Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
The primary purpose of this study is to assess the safety and tolerability of AB598 in participants with advanced malignancies.
Advanced Cancer|Advanced Malignancies|Bladder Cancer|Cervical Cancer|Esophageal Cancer|Gastric Cancer|Gastroesophageal-junction Cancer (GEJ)|Head and Neck Squamous Cell Carcinoma (HNSCC)|Non-Small Cell Lung Cancer (NSCLC)|Ovarian Cancer|Renal Cell Carcinoma (RCC)|Triple Negative Breast Cancer (TNBC)
DRUG: AB598|DRUG: Zimberelimab|DRUG: Fluorouracil|DRUG: Leucovorin|DRUG: Oxaliplatin
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs), Up to 2 years|Dose Escalation Cohorts: Number of Participants with Dose-Limiting Toxicities (DLTs), Up to 2 years
Area Under the Concentration-Time Curve from Administration ("0") to the Time That the Drug is No Longer Present in the Body ("infinity") (AUC 0-inf) in Whole Blood and Plasma, Predose, Up to 4 hours post dose|Maximum Concentration (Cmax) in Whole Blood and Plasma, Predose, Up to 4 hours post dose|Time to Maximum Concentration (Tmax) in Whole Blood and Plasma, Predose, Up to 4 hours post dose|Number of Participants Who Test Positive for Antidrug Antibodies (ADAs) to AB598, Up to 2 years|Objective Response Rate (ORR), Up to 2 years|Dose Expansion Cohort: Duration of Response (DOR), Up to 2 years
The primary purpose of this study is to assess the safety and tolerability of AB598 in participants with advanced malignancies.